Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belzutifan in Phaeochromocytoma and Paraganglioma
NCT07680205Phase 2Recruiting
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
- Start
- Apr 2026
- Primary completion
- Apr 2027
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of belzutifan in pheochromocytoma and Paraganglioma (PGL), sponsored by Cambridge University Hospitals NHS Foundation Trust. Primary endpoint: Tyrosine measurements at day 14. Started Apr 2026; status: recruiting.
02
Drugs
belzutifan
03
Conditions
pheochromocytomaParaganglioma (PGL)
Beyond the preview
Go deeper on NCT07680205.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07680205.